Caricamento...
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...
Salvato in:
| Pubblicato in: | BMC Hematol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://ncbi.nlm.nih.gov/pubmed/26167286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-015-0029-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|